{"id":"gardasil9","safety":{"commonSideEffects":[{"rate":"60–70%","effect":"Injection site pain"},{"rate":"25–35%","effect":"Injection site swelling"},{"rate":"20–30%","effect":"Injection site erythema"},{"rate":"10–15%","effect":"Headache"},{"rate":"1–3%","effect":"Fever"},{"rate":"5–10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL6068359","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains virus-like particles (VLPs) derived from the L1 major capsid protein of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. When administered, these VLPs trigger a humoral immune response that generates neutralizing antibodies against these HPV types, preventing viral infection of epithelial cells and reducing the risk of HPV-related malignancies and benign lesions.","oneSentence":"Gardasil9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:52.514Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58"},{"name":"Prevention of anal cancer caused by HPV types 16 and 18"},{"name":"Prevention of genital warts caused by HPV types 6 and 11"},{"name":"Prevention of oropharyngeal and other head and neck cancers caused by HPV types 16 and 18"}]},"trialDetails":[{"nctId":"NCT07407569","phase":"PHASE2","title":"Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2026-03-25","conditions":"Human Papilloma Virus Infection Type 16","enrollment":50},{"nctId":"NCT02568566","phase":"PHASE2","title":"Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-19","conditions":"Human Papillomavirus-Related Carcinoma","enrollment":201},{"nctId":"NCT05985681","phase":"PHASE1","title":"Testing RG1-VLP Vaccine to Prevent HPV-related Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-27","conditions":"Human Papillomavirus-Related Carcinoma","enrollment":18},{"nctId":"NCT05237947","phase":"PHASE4","title":"Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":5000},{"nctId":"NCT03519464","phase":"PHASE2","title":"Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-02-04","conditions":"Idiopathic CD4 T Cell Lymphocytopenia","enrollment":54},{"nctId":"NCT06658405","phase":"PHASE2","title":"Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2025-01-13","conditions":"Cervical Lesion","enrollment":85},{"nctId":"NCT03943875","phase":"PHASE4","title":"GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2019-06-17","conditions":"Immunization, Efficacy, Human Papilloma Virus","enrollment":767},{"nctId":"NCT03036930","phase":"PHASE2","title":"Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma","enrollment":51},{"nctId":"NCT05334706","phase":"PHASE4","title":"A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)","status":"RECRUITING","sponsor":"Miquel Angel Pavon Ribas","startDate":"2022-09-13","conditions":"Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV","enrollment":69},{"nctId":"NCT07303751","phase":"PHASE2","title":"Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV","status":"NOT_YET_RECRUITING","sponsor":"Institut d'Investigació Biomèdica de Bellvitge","startDate":"2026-02-01","conditions":"HPV, High-risk HPV (Any Strain), Human Papillomavirus (HPV) Infections","enrollment":80},{"nctId":"NCT05495906","phase":"PHASE4","title":"A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2023-07-27","conditions":"HPV, Human Papilloma Virus, Human Immunodeficiency Virus","enrollment":275},{"nctId":"NCT03979014","phase":"PHASE3","title":"Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-11-01","conditions":"Neoplasia","enrollment":1099},{"nctId":"NCT03284866","phase":"PHASE3","title":"HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2019-07-31","conditions":"AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection","enrollment":536},{"nctId":"NCT06752083","phase":"","title":"Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection","status":"COMPLETED","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2023-01-02","conditions":"HPV Infection","enrollment":289},{"nctId":"NCT04206813","phase":"PHASE4","title":"An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Medical Center","startDate":"2020-12-01","conditions":"HPV Infection","enrollment":352},{"nctId":"NCT04255849","phase":"PHASE3","title":"Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-02-23","conditions":"HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection","enrollment":700},{"nctId":"NCT07339163","phase":"PHASE1, PHASE2","title":"Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*","status":"NOT_YET_RECRUITING","sponsor":"Ohio State University","startDate":"2026-04-01","conditions":"Recurrent Respiratory Papillomatosis (RRP)","enrollment":50},{"nctId":"NCT06786429","phase":"PHASE4","title":"Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","status":"NOT_YET_RECRUITING","sponsor":"Eunice Dube","startDate":"2026-08-30","conditions":"Hepatitis B, Human Papilloma Virus, Gall Stones (& [Calculus - Gall Bladder])","enrollment":1800},{"nctId":"NCT06411938","phase":"NA","title":"A Cervical Cancer Prevention Program in Kenya","status":"ACTIVE_NOT_RECRUITING","sponsor":"Indiana University","startDate":"2024-04-02","conditions":"Cervical Cancer Prevention, Cervical Cancer","enrollment":2300},{"nctId":"NCT07240220","phase":"NA","title":"The Mother-Daughter Project: Merck-4","status":"NOT_YET_RECRUITING","sponsor":"Indiana University","startDate":"2026-02-01","conditions":"Cervical Dysplasia","enrollment":2500},{"nctId":"NCT07314307","phase":"PHASE4","title":"Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska Institutet","startDate":"2021-05-03","conditions":"Incident HPV16, 18, 31, 33, 45, 52 or 58 Infection","enrollment":150000},{"nctId":"NCT04945655","phase":"NA","title":"Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2021-11-15","conditions":"HPV Vaccine Acceptability","enrollment":30739},{"nctId":"NCT03023631","phase":"PHASE4","title":"Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-04-23","conditions":"Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":48},{"nctId":"NCT05031078","phase":"PHASE4","title":"Assessing Durable Antibody Response to HPV Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-12-21","conditions":"HPV","enrollment":17},{"nctId":"NCT04265950","phase":"PHASE4","title":"Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-03-10","conditions":"HIV Infection","enrollment":97},{"nctId":"NCT05672927","phase":"PHASE4","title":"Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)","status":"RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2023-01-18","conditions":"Immunization, HPV Infection, Human Papillomavirus","enrollment":618},{"nctId":"NCT05087849","phase":"PHASE1, PHASE2","title":"Intralesional HPV Vaccine for Condylomata","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2022-04-15","conditions":"Human Papilloma Virus, Warts, Warts, Genital","enrollment":2},{"nctId":"NCT06229353","phase":"","title":"Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2024-08-08","conditions":"Human Papilloma Virus","enrollment":34},{"nctId":"NCT07156084","phase":"PHASE4","title":"Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-09-23","conditions":"HPV Vaccine","enrollment":300},{"nctId":"NCT02834637","phase":"PHASE3","title":"A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls","status":"ACTIVE_NOT_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-02-23","conditions":"Human Papilloma Virus","enrollment":930},{"nctId":"NCT03180034","phase":"PHASE4","title":"Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-29","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma","enrollment":27945},{"nctId":"NCT04982614","phase":"PHASE4","title":"HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini","status":"COMPLETED","sponsor":"Columbia University","startDate":"2022-04-01","conditions":"HPV Infection, Hiv, HPV Vaccine","enrollment":1403},{"nctId":"NCT06799494","phase":"PHASE4","title":"HPV Vaccine Reduced Dose","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-08-06","conditions":"HPV","enrollment":100},{"nctId":"NCT06967740","phase":"","title":"Epidemiological Factors and Optimization of Conservative Approaches to Precancerous Lesions of Female Reproductive Organs","status":"RECRUITING","sponsor":"Nikola Janovska","startDate":"2024-11-01","conditions":"Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Risk Factors","enrollment":200},{"nctId":"NCT06414057","phase":"","title":"HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-07-07","conditions":"Human Papilloma Virus","enrollment":500},{"nctId":"NCT05557370","phase":"PHASE4","title":"Immunogenicity of HPV Vaccine in Transplant Recipients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-01","conditions":"Chronic Kidney Diseases, Kidney Transplant","enrollment":30},{"nctId":"NCT05329961","phase":"EARLY_PHASE1","title":"Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Medical Center","startDate":"2022-09-26","conditions":"Human Papilloma Virus","enrollment":155},{"nctId":"NCT06588257","phase":"PHASE4","title":"Acceptability of the HPV Vaccine and Anal HPV in Transgender Women and Men Who Have Sex With Men: A Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Huésped","startDate":"2024-10-09","conditions":"HPV","enrollment":101},{"nctId":"NCT06793410","phase":"PHASE2","title":"Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-05-12","conditions":"Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated, Acute Myeloid Leukaemia","enrollment":100},{"nctId":"NCT06624839","phase":"PHASE2","title":"Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-03-15","conditions":"Human Papilloma Virus, Anal Dysplasia, HIV","enrollment":120},{"nctId":"NCT05266898","phase":"PHASE4","title":"Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2022-11-30","conditions":"Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection","enrollment":250},{"nctId":"NCT04235257","phase":"PHASE4","title":"Intradermal, Fractional Dose of HPV Vaccines:","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2020-11-01","conditions":"HPV Infection, HPV Vaccine","enrollment":40},{"nctId":"NCT01824537","phase":"PHASE4","title":"Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study","status":"COMPLETED","sponsor":"McGill University","startDate":"2014-01","conditions":"Human Papillomavirus Infection","enrollment":372},{"nctId":"NCT03391921","phase":"PHASE4","title":"Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2018-01-08","conditions":"HPV - Anogenital Human Papilloma Virus Infection, HIV Infections","enrollment":170},{"nctId":"NCT05496231","phase":"PHASE1, PHASE2","title":"A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-08-22","conditions":"Cervical Intraepithelial Neoplasia","enrollment":1080},{"nctId":"NCT04814446","phase":"PHASE3","title":"Nonavalent HPV Vaccine in the Treatment of Difficult-to-treat Palmo-plantar Warts","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-29","conditions":"Palmar or Plantar Warts","enrollment":146},{"nctId":"NCT05202860","phase":"PHASE2","title":"Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merete Haedersdal","startDate":"2022-05-09","conditions":"Actinic Keratoses, Basal Cell Carcinoma, Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT06681636","phase":"PHASE2","title":"Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Hygiene and Epidemiology, Vietnam","startDate":"2024-12-14","conditions":"HPV Infection, Cervical Cancer, Anogenital Cancer","enrollment":300},{"nctId":"NCT06582654","phase":"","title":"Normalizing Antibody Detection in First-void Urine","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2023-12-07","conditions":"Human Papillomavirus Infection","enrollment":150},{"nctId":"NCT06536855","phase":"PHASE4","title":"Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda","status":"NOT_YET_RECRUITING","sponsor":"Rwanda Biomedical Centre","startDate":"2024-09-01","conditions":"Cervical Cancer","enrollment":100000},{"nctId":"NCT05625633","phase":"PHASE2, PHASE3","title":"Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts","status":"RECRUITING","sponsor":"Western Institute for Veterans Research","startDate":"2024-03-25","conditions":"Warts","enrollment":120},{"nctId":"NCT03051516","phase":"PHASE4","title":"HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2017-08-01","conditions":"High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion","enrollment":188},{"nctId":"NCT03675256","phase":"PHASE4","title":"The KEN SHE Study on HPV-vaccine Efficacy","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2018-12-19","conditions":"Papillomavirus Infections","enrollment":2275},{"nctId":"NCT06052696","phase":"PHASE4","title":"Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2023-12-01","conditions":"Vulvar HSIL, HPV","enrollment":500},{"nctId":"NCT04274153","phase":"PHASE4","title":"HPV Vaccination Study in Postpartum Women","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-08-03","conditions":"HPV, Immunization, Human Papilloma Virus","enrollment":225},{"nctId":"NCT03626467","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2018-10-15","conditions":"HIV Infections","enrollment":158},{"nctId":"NCT03350698","phase":"PHASE4","title":"Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination","status":"UNKNOWN","sponsor":"Eastern Virginia Medical School","startDate":"2018-04-06","conditions":"Papillomavirus Vaccines","enrollment":100},{"nctId":"NCT05680454","phase":"PHASE1","title":"A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine","status":"COMPLETED","sponsor":"Beijing Health Guard Biotechnology, Inc","startDate":"2019-09-01","conditions":"Human Papillomavirus Infection","enrollment":160},{"nctId":"NCT05580341","phase":"PHASE3","title":"Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9","status":"UNKNOWN","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2022-09-01","conditions":"Cervical Cancer, Genital Wart, CIN","enrollment":1200},{"nctId":"NCT05450705","phase":"PHASE3","title":"V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-22","conditions":"Papillomavirus Infections","enrollment":1500},{"nctId":"NCT03947775","phase":"PHASE2","title":"HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-09-01","conditions":"Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus","enrollment":228},{"nctId":"NCT04436133","phase":"PHASE2","title":"Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2020-06-20","conditions":"HPV Infection, HPV-Related Cervical Carcinoma","enrollment":480},{"nctId":"NCT03832049","phase":"PHASE3","title":"HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-09-14","conditions":"Human Papillomavirus Vaccine","enrollment":1720},{"nctId":"NCT04459221","phase":"PHASE4","title":"Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2020-11-01","conditions":"Papilloma Viral Infection","enrollment":355},{"nctId":"NCT01492582","phase":"PHASE2","title":"Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2012-07","conditions":"Cancer Survivor, Prevention of Human Papillomavirus Infection","enrollment":1499},{"nctId":"NCT03451071","phase":"PHASE4","title":"Postpartum HPV Vaccination","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2019-04-29","conditions":"HPV-Related Malignancy","enrollment":195},{"nctId":"NCT04910802","phase":"PHASE4","title":"Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden","status":"RECRUITING","sponsor":"Miriam Elfström","startDate":"2021-05-03","conditions":"HPV Infection, CIN 2/3, Cervical Cancer","enrollment":150000},{"nctId":"NCT04430907","phase":"","title":"HPV Vaccine in Postpartum Women","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2021-09","conditions":"HPV Infection","enrollment":""},{"nctId":"NCT02968420","phase":"PHASE4","title":"Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2017-09-11","conditions":"Human Papillomavirus","enrollment":18},{"nctId":"NCT03525210","phase":"PHASE3","title":"Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2018-04-04","conditions":"Human Papilloma Virus, Hiv, Organ Transplants","enrollment":271},{"nctId":"NCT03848039","phase":"PHASE3","title":"Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9","status":"NOT_YET_RECRUITING","sponsor":"Alessandro Ghelardi","startDate":"2020-12","conditions":"Cervical Intraepithelial Neoplasia","enrollment":1220},{"nctId":"NCT02567955","phase":"PHASE3","title":"Immunogenicity and Safety of Gardasil-9 and Cervarix","status":"COMPLETED","sponsor":"Laval University","startDate":"2015-09","conditions":"HPV Vaccines Immunogenicity and Safety","enrollment":376},{"nctId":"NCT03431246","phase":"PHASE3","title":"Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9","status":"COMPLETED","sponsor":"Laval University","startDate":"2016-10-01","conditions":"Human Papillomavirus Vaccines","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GARDASIL®","G9","SILGARD®9","V503","Recombinant 9 valent human papillomavirus vaccine"],"phase":"marketed","status":"active","brandName":"Gardasil9","genericName":"Gardasil9","companyName":"Boston Medical Center","companyId":"boston-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gardasil9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers. Used for Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58, Prevention of anal cancer caused by HPV types 16 and 18, Prevention of genital warts caused by HPV types 6 and 11.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}